Updates are available Correction dated 2022-07-20
Click to view Correction: https://doi.org/10.1038/s41591-022-01952-7
-
Authors
Choutka, Jan http://orcid.org/0000-0001-6290-9787
Jansari, Viraj
Hornig, Mady http://orcid.org/0000-0001-7572-3092
Iwasaki, Akiko http://orcid.org/0000-0002-7824-9856
-
Funding
Funding for this research was provided by:
Howard Hughes Medical Institute (N/A)
- License Information
-
More Information
Article History
Received: 23 November 2021
Accepted: 1 April 2022
First Online: 18 May 2022
Change Date: 20 July 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-022-01952-7
Competing interests
: J. C. receives financial support from Gilead Sciences & IOCB Research Centre and is involved in running Czech Association of patients with ME/CFS — a volunteer non-profit initiative supporting patients with ME/CFS (no funds involved). V. J. declares no competing interests. M. H. serves on the scientific advisory boards of PaxMedica and Simmaron Research. A. I. consults for 4BIO Capital, BlueWillow Biologics, Healthspan Technologies, Revelar Biotherapeutics, RIGImmune, and Xanadu Bio.
Free to read: This content has been made available to all.
